Why selling to Novartis made sense for Mariana - BioPharma Dive

May 3, 2024 · A new plant in Indianapolis came on line earlier this year, for example, increasing the number of doses Novartis can make annually to 250,000. “It was a significant investment …

CouponFollow Extension

$1
OFF

BioPharma Dive On LinkedIn: Why Selling To Novartis Made Sense …

22 hours ago

Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."

linkedin.com

$1
OFF

Novartis Wagers More Than $1B On Gene Therapies For The Nervous …

22 hours ago

Nov 21, 2024 · DTx was one in a series of smaller-scale purchases Novartis made over the past couple years. The company snagged the radiopharmaceutical developer Mariana Oncology for …

biopharmadive.com

$140
OFF

BioPharma Dive’s Post - LinkedIn

22 hours ago

The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies. AstraZeneca ups stake in …

linkedin.com

29%
OFF

Top Novartis Executives To Depart As Company Restructures

22 hours ago

Apr 4, 2022 · Currently, Novartis' selling, general and administrative expenses make up about 29% of sales, higher than many of its drugmaker peers. Reducing those costs is a key part of …

biopharmadive.com

$300
OFF

Novartis Funnels $300M Into Early Biologic Drug Manufacturing

22 hours ago

Sep 12, 2022 · Novartis will also spend $100 million to establish a biologics hub near its Novartis Institutes of BioMedical Research biologics center in Switzerland to foster research and attract …

biopharmadive.com

FAQs about Why selling to Novartis made sense for Mariana - BioPharma Dive Coupon?

Will Novartis pay $1 billion for Mariana oncology?

Novartis has struck another deal to strengthen its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology. ...

What role did Mark Fishman have at Novartis?

Mark Fishman was the predecessor of Alasdair Bradner at Novartis, leading the organization before Bradner took over drug discovery and early clinical development efforts. During Fishman's tenure, Novartis focused more on cancer research and restructured its R&D organization. Novartis also pursued new approaches to gene therapy and cancer cell therapies. ...

Which executives are leaving Novartis?

Some executives are leaving Novartis. Tsai, who has been Novartis’ chief medical officer since joining from Amgen in 2018, is leaving the company. Susanne Schaffert, the oncology chief, and the head of Novartis’ customer and technology unit, Robert Weltevreden, are also leaving. ...

Will Novartis merge its pharmaceutical and oncology business units?

Novartis will merge its pharmaceutical and oncology business units into an ‘innovative medicines’ division. This division will be responsible for finding and developing prescription drugs. The commercial arms of this division will be organized to focus separately on U.S. and international markets. ...

Can Novartis save $1 billion a year by 2024?

Novartis plans to save $1 billion annually by 2024 as part of its cost reduction efforts. The company also aims to raise the margins for its innovative medicines business to more than 40% in the mid- to long-term. ...

Does novartis'synergy' save money?

A large portion of the cost savings from Novartis' restructuring will come from synergies within the technical operations unit. So, oncology chief Susanne Schaffert and the head of Novartis’ customer and technology unit, Robert Weltevreden, are among the executives set to depart. ...